The primary purpose of this project is to determine the effect of morning bright light therapy (MBLT) on sleep in Veterans with traumatic brain injury (TBI). Secondarily, the project aims to identify blood-based brain biomarkers (BBBM) associated with sleep in Veterans.
Specific Aim 1. Determine the effect of MBLT on sleep quality in Veterans (primary outcome).
Specific Aim 2. Determine the effect of MBLT on downstream effectors of improved sleep, including cognition, mood, and quality of life measures in Veterans (exploratory outcomes).
Specific Aim 3. Determine the effect of MBLT on levels of specific BBBM related to sleep, and whether changes in specific BBBM predict response to MBLT (secondary outcome).
This study can now be completed 100% remotely.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Traumatic Brain Injury | Device: Light box therapy Device: Negative Ion Generator | Not Applicable |
This project will utilize a biobehavioral intervention to improve sleep and apply a novel approach to measuring biomarkers in Veterans with TBI. The investigators will use morning bright light therapy (MBLT) to improve sleep. MBLT acts through intrinsically photosensitive retinal ganglion cells and has pleiotropic effects on sleep, circadian rhythms, cognition, mood, and pain through activation of brain circuits.
MBLT is a simple, cost-effective, home-based sleep intervention. It has been studied in a variety of neuropsychiatric populations, such as seasonal affective disorder, non-seasonal depression, Alzheimer's, Huntington's, Parkinson's disease, and schizophrenia. MBLT is an attractive intervention for TBI as patients typically report multiple concomitant symptoms including alterations in mood and alertness (daytime fatigue). One recent placebo-controlled study using MBLT reported improved fatigue in individuals with TBI. Moreover, MBLT has high patient acceptability and is scalable, owing to its ability to be rapidly implemented in any setting including in the home or in a rehabilitation facility.
To address the substantial limitation of using peripheral biomarkers to understand central pathophysiology in TBI, the investigators have developed a method to use blood-based brain biomarkers (BBBM) to track central pathophysiology and symptomatology of TBI and response to treatment. This method entails isolation of neuronally derived exosomes in peripheral blood. Exosomes are membrane bound structures that, instead of being delivered to lysosomes for destruction, reside in multivesicular bodies, fuse with the plasma membrane, and are exocytosed into extracellular spaces. Within the membrane of exosomes are various proteins present in the cell of origin; thus, the cargo of exosomes reflects the microenvironment from the site of exosome production. Exosomes hold promise in TBI since they can readily cross the blood brain barrier (BBB) and be isolated from peripheral circulation. Studying exosomes allows us to isolate those proteins that are routinely disrupted in patients with TBI and sleep disturbances, and to track changes in accordance with treatment condition over time.
In this project, the investigators will conduct a randomized controlled, single blinded trial in which Veterans with and without TBI will receive MBLT or sham (modified negative ion generator; see below for modification specifications) for 4-weeks. BBBM will be assessed in conjunction with MBLT/sham and neurobehavioral symptomatology. The investigators hypothesize that: 1) MBLT will be associated with improved sleep, and downstream effectors of improved sleep (i.e., cognition, mood, and quality of life), compared to the sham condition; 2) MBLT will show a correlation between BBBM and improved sleep, and levels of BBBM will predict those that respond to MBLT. This will provide novel insights into how these biomarkers relate to neuronal and behavioral changes following TBI and may inform trajectory of recovery.
The study can be completed 100% remotely, in person, or a combination of the two.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 300 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Single (Participant) |
| Primary Purpose: | Treatment |
| Official Title: | Improving Sleep, Sleep-related Outcomes, and Biomarkers in Veterans |
| Actual Study Start Date : | August 1, 2019 |
| Estimated Primary Completion Date : | August 1, 2024 |
| Estimated Study Completion Date : | August 1, 2025 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Light box
Commercially available lightbox emitting 10,000 lux of light. Subjects asked to use lightbox everyday for an hour for 4 weeks upon waking.
|
Device: Light box therapy
The intervention is sitting in front of a lightbox for 1 hour in the morning upon waking up.
|
|
Sham Comparator: Negative Ion Generator
Commercially available negative ion generator. Subjects asked to use everyday for an hour for 4 weeks upon waking.
|
Device: Negative Ion Generator
The intervention is sitting in front of a modified negative ion generator for 1 hour in the morning upon waking up.
|
| Ages Eligible for Study: | 18 Years to 88 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
| Contact: Miranda Lim, MD, PhD | 503-220-8262 ext 57404 | lmir@ohsu.edu |
| United States, Oregon | |
| Portland VA Medical Center | Recruiting |
| Portland, Oregon, United States, 97239 | |
| Contact: Miranda M Lim, MD, PhD lmir@ohsu.edu | |
| Principal Investigator: | Miranda Lim, MD, PhD | Portland VA |
| Tracking Information | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First Submitted Date ICMJE | May 23, 2019 | ||||||||||||||||||
| First Posted Date ICMJE | May 30, 2019 | ||||||||||||||||||
| Last Update Posted Date | March 11, 2021 | ||||||||||||||||||
| Actual Study Start Date ICMJE | August 1, 2019 | ||||||||||||||||||
| Estimated Primary Completion Date | August 1, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||||||
| Current Primary Outcome Measures ICMJE |
Change in Insomnia Severity Index (ISI) [ Time Frame: Baseline; after 4 weeks of intervention; and 2 months after the end of intervention ] Measures self-reported insomnia severity; total score range = 0-28 (higher total score = worse insomnia)
|
||||||||||||||||||
| Original Primary Outcome Measures ICMJE | Same as current | ||||||||||||||||||
| Change History | |||||||||||||||||||
| Current Secondary Outcome Measures ICMJE |
Change in NFL, GFAP, UCH-L1, and total tau [ Time Frame: Baseline; after 4 weeks of intervention; and 2 months after the end of intervention ] Change in neurofilament light chain (NFL), glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1), and total tau
|
||||||||||||||||||
| Original Secondary Outcome Measures ICMJE | Same as current | ||||||||||||||||||
| Current Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||||
| Original Other Pre-specified Outcome Measures | Not Provided | ||||||||||||||||||
| Descriptive Information | |||||||||||||||||||
| Brief Title ICMJE | Improving Sleep, Sleep-related Outcomes, and Biomarkers in Veterans | ||||||||||||||||||
| Official Title ICMJE | Improving Sleep, Sleep-related Outcomes, and Biomarkers in Veterans | ||||||||||||||||||
| Brief Summary |
The primary purpose of this project is to determine the effect of morning bright light therapy (MBLT) on sleep in Veterans with traumatic brain injury (TBI). Secondarily, the project aims to identify blood-based brain biomarkers (BBBM) associated with sleep in Veterans. Specific Aim 1. Determine the effect of MBLT on sleep quality in Veterans (primary outcome). Specific Aim 2. Determine the effect of MBLT on downstream effectors of improved sleep, including cognition, mood, and quality of life measures in Veterans (exploratory outcomes). Specific Aim 3. Determine the effect of MBLT on levels of specific BBBM related to sleep, and whether changes in specific BBBM predict response to MBLT (secondary outcome). This study can now be completed 100% remotely. |
||||||||||||||||||
| Detailed Description |
This project will utilize a biobehavioral intervention to improve sleep and apply a novel approach to measuring biomarkers in Veterans with TBI. The investigators will use morning bright light therapy (MBLT) to improve sleep. MBLT acts through intrinsically photosensitive retinal ganglion cells and has pleiotropic effects on sleep, circadian rhythms, cognition, mood, and pain through activation of brain circuits. MBLT is a simple, cost-effective, home-based sleep intervention. It has been studied in a variety of neuropsychiatric populations, such as seasonal affective disorder, non-seasonal depression, Alzheimer's, Huntington's, Parkinson's disease, and schizophrenia. MBLT is an attractive intervention for TBI as patients typically report multiple concomitant symptoms including alterations in mood and alertness (daytime fatigue). One recent placebo-controlled study using MBLT reported improved fatigue in individuals with TBI. Moreover, MBLT has high patient acceptability and is scalable, owing to its ability to be rapidly implemented in any setting including in the home or in a rehabilitation facility. To address the substantial limitation of using peripheral biomarkers to understand central pathophysiology in TBI, the investigators have developed a method to use blood-based brain biomarkers (BBBM) to track central pathophysiology and symptomatology of TBI and response to treatment. This method entails isolation of neuronally derived exosomes in peripheral blood. Exosomes are membrane bound structures that, instead of being delivered to lysosomes for destruction, reside in multivesicular bodies, fuse with the plasma membrane, and are exocytosed into extracellular spaces. Within the membrane of exosomes are various proteins present in the cell of origin; thus, the cargo of exosomes reflects the microenvironment from the site of exosome production. Exosomes hold promise in TBI since they can readily cross the blood brain barrier (BBB) and be isolated from peripheral circulation. Studying exosomes allows us to isolate those proteins that are routinely disrupted in patients with TBI and sleep disturbances, and to track changes in accordance with treatment condition over time. In this project, the investigators will conduct a randomized controlled, single blinded trial in which Veterans with and without TBI will receive MBLT or sham (modified negative ion generator; see below for modification specifications) for 4-weeks. BBBM will be assessed in conjunction with MBLT/sham and neurobehavioral symptomatology. The investigators hypothesize that: 1) MBLT will be associated with improved sleep, and downstream effectors of improved sleep (i.e., cognition, mood, and quality of life), compared to the sham condition; 2) MBLT will show a correlation between BBBM and improved sleep, and levels of BBBM will predict those that respond to MBLT. This will provide novel insights into how these biomarkers relate to neuronal and behavioral changes following TBI and may inform trajectory of recovery. The study can be completed 100% remotely, in person, or a combination of the two. |
||||||||||||||||||
| Study Type ICMJE | Interventional | ||||||||||||||||||
| Study Phase ICMJE | Not Applicable | ||||||||||||||||||
| Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Single (Participant) Primary Purpose: Treatment |
||||||||||||||||||
| Condition ICMJE | Traumatic Brain Injury | ||||||||||||||||||
| Intervention ICMJE |
|
||||||||||||||||||
| Study Arms ICMJE |
|
||||||||||||||||||
| Publications * | Not Provided | ||||||||||||||||||
|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||||||
| Recruitment Information | |||||||||||||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||||||||||||
| Estimated Enrollment ICMJE |
300 | ||||||||||||||||||
| Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||||||
| Estimated Study Completion Date ICMJE | August 1, 2025 | ||||||||||||||||||
| Estimated Primary Completion Date | August 1, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||||||
| Eligibility Criteria ICMJE |
Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||||||
| Sex/Gender ICMJE |
|
||||||||||||||||||
| Ages ICMJE | 18 Years to 88 Years (Adult, Older Adult) | ||||||||||||||||||
| Accepts Healthy Volunteers ICMJE | Yes | ||||||||||||||||||
| Contacts ICMJE |
|
||||||||||||||||||
| Listed Location Countries ICMJE | United States | ||||||||||||||||||
| Removed Location Countries | |||||||||||||||||||
| Administrative Information | |||||||||||||||||||
| NCT Number ICMJE | NCT03968874 | ||||||||||||||||||
| Other Study ID Numbers ICMJE | MIRB #4268, eIRB #19411 | ||||||||||||||||||
| Has Data Monitoring Committee | No | ||||||||||||||||||
| U.S. FDA-regulated Product |
|
||||||||||||||||||
| IPD Sharing Statement ICMJE |
|
||||||||||||||||||
| Responsible Party | Miranda M Lim, Portland VA Medical Center | ||||||||||||||||||
| Study Sponsor ICMJE | Portland VA Medical Center | ||||||||||||||||||
| Collaborators ICMJE | Center for Neuroscience and Regenerative Medicine (CNRM) | ||||||||||||||||||
| Investigators ICMJE |
|
||||||||||||||||||
| PRS Account | Portland VA Medical Center | ||||||||||||||||||
| Verification Date | March 2021 | ||||||||||||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||||||||||||